Ubidecarenone
C59H90O4863.37
2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl]-5,6-dimethoxy-3-methyl;
2-[(all-E)-3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-p-benzoquinone
[303-98-0].
+'&img=../../images/v35300/cas-303-98-0.gif&casNumber=303-98-0&usp=35&nf=30&chemicalStructureImage=true&ID='+parent.myID,600,500);)
+'&img=../../images/v35300/cas-303-98-0.gif&casNumber=303-98-0&usp=35&nf=30&chemicalStructureImage=true&ID='+parent.myID,600,500);){kind=small}
C59H90O4863.37
2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl]-5,6-dimethoxy-3-methyl;
2-[(all-E)-3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-p-benzoquinone
[303-98-0].DEFINITION
Ubidecarenone (Coenzyme Q10) contains NLT 98.0% and NMT 101.0% of ubidecarenone (C59H90O4), calculated on the anhydrous basis.
IDENTIFICATION
• B.
Analysis: Dissolve 50 mg of Ubidecarenone in 1 mL of ethyl ether, and add 10 mL of dehydrated alcohol. To 2 mL of this solution add 3 mL of dehydrated alcohol and 2 mL of dimethyl malonate. Add 1 mL of potassium hydroxide solution (1 in 5) dropwise.
Acceptance criteria: A blue color appears.
ASSAY
• Procedure
Mobile phase: Methanol and dehydrated alcohol (65:35)
System suitability solution: 0.5 mg/mL each of USP Ubidecarenone RS and USP Ubidecarenone Related Compound A RS in dehydrated alcohol. Heat at 50
for 2 min, if necessary, for complete dissolution.
for 2 min, if necessary, for complete dissolution.Standard solution: 1.0 mg/mL of USP Ubidecarenone RS in dehydrated alcohol. Heat at 50 for 2 min, if necessary, for complete dissolution.
for 2 min, if necessary, for complete dissolution.Sample solution: 1.0 mg/mL of Ubidecarenone in dehydrated alcohol. Heat at 50 for 2 min, if necessary, for complete dissolution.
for 2 min, if necessary, for complete dissolution.Chromatographic system
Mode: LC
Detector: UV 275 nm
Column: 4.6-mm × 15-cm; packing L1
Column temperature: 35
Flow rate: Adjust to obtain a retention time of about 11 min for ubidecarenone.
Injection size: 5 µL
System suitability
Sample: System suitability solution
[Note—The relative retention times for ubidecarenone related compound A and ubidecarenone are about 0.75 and 1.0, respectively. ]
Suitability requirements
Resolution: NLT 4 between ubidecarenone related compound A and ubidecarenone
Relative standard deviation: NMT 0.8% for ubidecarenone
Analysis
Samples: Standard solution and Sample solution
Calculate the percentage of ubidecarenone (C59H90O4) in the portion of Ubidecarenone taken:
Result = (rU/rS) × (CS/CU) × 100
| rU | = | = peak response from the Sample solution |
| rS | = | = peak response from the Standard solution |
| CS | = | = concentration of USP Ubidecarenone RS in the Standard solution (mg/mL) |
| CU | = | = concentration of Ubidecarenone in the Sample solution (mg/mL) |
Acceptance criteria: 98.0%–101.0% on the anhydrous basis
IMPURITIES
• Residue on Ignition 
281
: NMT 0.1%
281: NMT 0.1%• Heavy Metals, Method II 231: NMT 20 ppm
231: NMT 20 ppm• Chromatographic Purity
Procedure 1: Coenzymes Q7,Q8, Q9, Q11, and Related Impurities
Mobile phase, System suitability solution, Sample solution, Chromatographic system, and System suitability: Proceed as directed in the Assay.
Analysis
Sample: Sample solution
Calculate the percentage of impurities in the portion of Ubidecarenone taken:
Result = (rT1/rT2) × 100
| rT1 | = | = sum of all peak responses, other than that for ubidecarenone |
| rT2 | = | = sum of all peak responses |
Acceptance criteria: NMT 1.0%
Procedure 2: Ubidecarenone (2Z)-Isomer and Related Impurities
Mobile phase: n-Hexane and ethyl acetate (97:3)
System suitability solution: 1 mg/mL of USP Ubidecarenone for System Suitability RS in n-hexane
Sample solution: 1 mg/mL of Ubidecarenone in n-hexane
Chromatographic system
Mode: LC
Detector: UV 275 nm
Column: 4.6-mm × 25-cm; packing L3
Flow rate: 2 mL/min
Injection size: 20 µL
System suitability
Sample: System suitability solution
[Note—The relative retention times for ubidecarenone (2Z)-isomer and ubidecarenone are about 0.85 and 1.0, respectively. ]
Suitability requirements
Resolution: NLT 1.5 between the ubidecarenone (2Z)-isomer and ubidecarenone
Analysis
Sample: Sample solution
Calculate the percentage of impurities in the portion of Ubidecarenone taken:
Result = (rT1/rT2) × 100
| rT1 | = | = sum of all peak responses, other than that for ubidecarenone |
| rT2 | = | = sum of all peak responses |
Acceptance criteria: NMT 1.0%
Total impurities: NMT 1.5%, obtained from Chromatographic Purity Procedures 1 and 2
SPECIFIC TESTS
• Water Determination, Method I 921: NMT 0.2%
921: NMT 0.2%ADDITIONAL REQUIREMENTS
• Packaging and Storage: Preserve in well-closed, light-resistant containers.
• USP Reference Standards 11
11 USP Ubidecarenone RS 
') + '&img=../../images/v35300/cas-303-98-0.gif',600,500);)
USP Ubidecarenone Related Compound A RS
[coenzyme Q9]
') + '&img=../../images/v35300/c11rs2029.gif',600,500);)
[coenzyme Q9]
USP Ubidecarenone for System Suitability RS
Auxiliary Information— Please check for your question in the FAQs before contacting USP.
| Topic/Question | Contact | Expert Committee |
|---|---|---|
| Monograph | Huy T. Dinh, M.S. Scientific Liaison 1-301-816-8594 | (DS2010) Monographs - Dietary Supplements |
| Reference Standards | RS Technical Services 1-301-816-8129 rstech@usp.org |
USP35–NF30 Page 1460
Pharmacopeial Forum: Volume No. 31(1) Page 86Chromatographic Column—
Chromatographic columns text is not derived from, and not part of, USP 35 or NF 30.